Ask AI
ProCE Banner Events

Evolving Evidence in First-Line Advanced Biliary Tract Cancer

This discussion will review mature data from pivotal immunotherapy-based trials and contextualize these findings with real-world experience from diverse patient populations. The program is designed to support attendees in understanding durability of benefit, safety considerations, and practical application of data to routine clinical practice.

Key Takeaways

  • Describe the current first-line treatment paradigm for advanced biliary tract cancer, including the role of immunotherapy-based combinations
  • Review long-term overall survival data from pivotal trials and discuss what extended follow-up reveals about durability of benefit
  • Evaluate emerging real-world evidence in advanced biliary tract cancer and consider how these data inform treatment decisions in routine clinical practice
Time and location

Tuesday, March 24, 2026

12:15 PM - 12:45 PM Pacific Time (PT)

Virtual